SR One, a trans-Atlantic biotech venture capital firm, announced today the close of its first independent fund, having recently completed its spinout from GlaxoSmithKline (GSK). GSK is the largest investor in the oversubscribed $500 million fund, joined by a global pool of institutional asset managers, endowments, foundations, pension funds and family offices. SR One will seek to continue to build elite biotechnology companies developing innovative medicines that address significant unmet needs.
{iframe}https://www.thedailytimes.com/business/sr-one-completes-spin-out-from-gsk-and-closes-first-fund-at-500-million/article_63de0aaf-8abf-57e7-b5d2-81930671db91.html{/iframe}